首页> 外文期刊>Frontiers in Pharmacology >Enhanced Anti-diabetic Effect of Berberine Combined With Timosaponin B2 in Goto-Kakizaki Rats, Associated With Increased Variety and Exposure of Effective Substances Through Intestinal Absorption
【24h】

Enhanced Anti-diabetic Effect of Berberine Combined With Timosaponin B2 in Goto-Kakizaki Rats, Associated With Increased Variety and Exposure of Effective Substances Through Intestinal Absorption

机译:小Go碱与Timosaponin B2联合在Goto-Kakizaki大鼠中的增强抗糖尿病作用,与增加品种和通过肠道吸收的有效物质暴露有关

获取原文
       

摘要

Objective: Inspired by the traditionally clinical application of herb pair Zhimu - Huangbo to treat diabetes, a combination of plant ingredients, timosaponin B2 (TB-2) and berberine (BBR), was evaluated for their anti-diabetic efficacy and cooperative mechanisms. Methods: The efficacy and pharmacokinetics of orally administered TB-2 (33.3 mg/kg/day), BBR (66.7 mg/kg/day), and TB-2+BBR (100 mg/kg/day) were evaluated in spontaneously non-obese diabetic Goto-Kakizaki (GK) rats, and metformin (200 mg/kg/day) was used as a positive control. The comparative exposure of the parent drugs, timosaponin A3 (TB-2 metabolite), and M1–M5 (BBR metabolites) was quantified in the portal vein plasma (before hepatic disposition), liver, and systemic plasma (after hepatic disposition) of normal rats on single and combination treatments. Cooperative mechanism of TB-2 and BBR on intestinal absorption and hepatic metabolism was investigated in Caco-2 cells and primary hepatocytes, respectively. Results: After a 6-week experiment, non-fasting and fasting blood glucose levels and oral glucose tolerance test results showed that TB-2+BBR treatments (100 mg/kg/day) displayed significantly anti-diabetic efficacy in GK rats, comparable to that on metformin treatments. However, no significant improvement was observed on TB-2 or BBR treatments alone. Compared to single treatments, combination treatments led to the increased circulating levels of BBR by 107% in GK rats. In normal rats, the hepatic exposure of BBR, timosaponin A3, and M1–M5 was several hundred folds higher than their circulating levels. Co-administration also improved the levels in the plasma and liver by 41–114% for BBR, 141–230% for TB-2, and 12–282% for M1–M5. In vitro , the interaction between TB-2 and BBR was mediated by intestinal absorption, rather than hepatic metabolism. Conclusion: Combining TB-2 and BBR enhanced the anti-diabetic efficacy by increasing the in vivo variety of effective substances, including the parent compounds and active metabolites, and improving the levels of those substances through intestinal absorption. This study is a new attempt to assess the effects of combined plant ingredients on diabetes by scientifically utilizing clinical experience of an herb pair.
机译:目的:在传统草药对知母-黄博对糖尿病治疗的传统启发下,评估植物成分,刺激素B2(TB-2)和小ber碱(BBR)的组合的抗糖尿病功效和协同机制。方法:以非自发方式评估口服TB-2(33.3 mg / kg /天),BBR(66.7 mg / kg /天)和TB-2 + BBR(100 mg / kg /天)的疗效和药代动力学。 -肥胖糖尿病的五岛崎崎(GK)大鼠,二甲双胍(200mg / kg /天)用作阳性对照。在正常肝的门静脉血浆(肝处置前),肝脏和全身血浆(肝处置后)中定量测定母体药物,刺激素A3(TB-2代谢物)和M1-M5(BBR代谢物)的相对暴露量。大鼠接受单一和联合治疗。分别在Caco-2细胞和原代肝细胞中研究了TB-2和BBR对肠道吸收和肝代谢的合作机制。结果:经过6周的实验,非空腹和空腹血糖水平以及口服葡萄糖耐量试验结果表明,TB-2 + BBR治疗(100 mg / kg /天)对GK大鼠具有明显的抗糖尿病作用,具有可比性与二甲双胍治疗有关。然而,仅TB-2或BBR治疗未见明显改善。与单一治疗相比,联合治疗导致GK大鼠的BBR循环水平提高了107%。在正常大鼠中,BBR,timosaponin A3和M1-M5的肝脏暴露量比其循环水平高数百倍。共同给药还可以使血浆和肝脏中BBR的水平提高41–114%,TB-2的水平提高141–230%,M1-M5的水平提高12–282%。在体外,TB-2和BBR之间的相互作用是通过肠道吸收而不是肝脏代谢来介导的。结论:TB-2和BBR的组合可通过增加体内有效物质(包括母体化合物和活性代谢物)的体内种类并通过肠道吸收提高这些物质的水平来增强抗糖尿病作用。这项研究是通过科学利用草药对的临床经验来评估组合植物成分对糖尿病的作用的新尝试。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号